PAI-1 deficiency reduces liver fibrosis after bile duct ligation in mice through activation of tPA  by Wang, Hongtao et al.
FEBS Letters 581 (2007) 3098–3104PAI-1 deﬁciency reduces liver ﬁbrosis after bile duct ligation in
mice through activation of tPA
Hongtao Wanga, Yan Zhangb,c, Robert O. Heuckerotha,*
a Division of Gastroenterology and Nutrition, Department of Pediatrics and Department of Molecular Biology and Pharmacology,
Washington University School of Medicine, 660 South Euclid Avenue, Box 8208, St. Louis, MO 63110, USA
b Division of Cardiology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA
c Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China
Received 19 March 2007; revised 8 May 2007; accepted 18 May 2007
Available online 29 May 2007
Edited by Veli-Pekka LehtoAbstract Plasminogen activator inhibitor-1 (PAI-1) increases
injury in several liver, lung and kidney disease models. The objec-
tive of this investigation was to assess the eﬀect of PAI-1 deﬁ-
ciency on cholestatic liver ﬁbrosis and determine PAI-1
inﬂuenced ﬁbrogenic mechanisms. We found that PAI-1/ mice
had less ﬁbrosis than wild type (WT) mice after bile duct liga-
tion. This change correlated with increased tissue-type plasmin-
ogen activator (tPA) activity, and increased matrix
metalloproteinase-9 (MMP-9), but not MMP-2 activity. Fur-
thermore, there was increased activation of the tPA substrate
hepatocyte growth factor (HGF), a known anti-ﬁbrogenic pro-
tein. In contrast, there was no diﬀerence in hepatic urokinase
plasminogen activator (uPA) or plasmin activities between
PAI-1/ and WT mice. There was also no diﬀerence in the level
of transforming growth factor beta 1 (TGF-b1), stellate cell acti-
vation or collagen production between WT and PAI-1/ ani-
mals. In conclusion, PAI-1 deﬁciency reduces hepatic ﬁbrosis
after bile duct obstruction mainly through the activation of
tPA and HGF.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Hepatocyte growth factor1. Introduction
Liver ﬁbrosis is the ﬁnal common pathway leading to liver
failure after many diﬀerent types of injury. The process from
initial insult to cirrhosis is a complex progression of necrosis/
apoptosis, cell proliferation, inﬂammation and extracellular
matrix deposition. Each aspect is controlled by speciﬁc molec-
ular mediators. Many of these mediators, including matrixAbbreviations: BDL, Bile duct ligation; HGF, hepatocyte growth
factor; MMP, matrix metalloproteinase; PAI-1, plasminogen activator
inhibitor-1; qRT-PCR, quantitative real time reverse transcriptase
polymerase chain reaction; TGF-b1, transforming growth factor-beta
1; tPA, tissue-type plasminogen activator; uPA, urokinase plasmino-
gen activator; WT, wild type
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1 (TGF-b1) and hepatocyte growth (HGF), are produced as
inactive precursors requiring proteolytic cleavage for activa-
tion. Therefore, controlled protease activity is essential in cel-
lular responses and extracellular matrix (ECM) remodeling
[1,2].
The plasmin protease system, consisting of plasminogen
activator inhibitor-1 (PAI-1), urokinase plasminogen activator
(uPA), tissue-type plasminogen activator (tPA) and plasmin, is
best understood for its role in blood ﬁbrinolysis [3]. PAI-1 pre-
vents the over-production of plasmin by blocking the activity
of tPA and uPA, proteases that convert the inactive protease
plasminogen to the active protease plasmin. PAI-1 is also
important in tissue remodeling and cell migration associated
with tissue repair [4]. For example, studies of PAI-1 over-
expression in transgenic mice demonstrate that PAI-1 pro-
motes ﬁbrin deposition and organ ﬁbrosis [5,6]. In contrast,
PAI-1 deﬁciency in mice attenuates kidney and lung ﬁbrosis
[6,7].
It was recently reported that PAI-1 deﬁciency also reduces
liver injury [2] and ﬁbrogenesis [8] in early stages (3–14 days)
after bile duct ligation (BDL). These studies demonstrate that
PAI-1 expression was signiﬁcantly elevated early after BDL
and that PAI-1 increases neutrophil inﬁltration and reduces
pro-HGF processing in mice. Furthermore, one of these stud-
ies demonstrated that PAI-1 deﬁcient mice have less collagen
accumulation in the liver 2 weeks after BDL than wild type
(WT) animals [8]. Whether PAI-1 deﬁciency results in less
ﬁbrosis at later time points after BDL is unknown, and the
mechanism of reduced ﬁbrosis in PAI-1/ mice after BDL re-
mains poorly understood. For example, PAI-1 deﬁciency
might be expected to increase the activity of plasminogen acti-
vators (tPA and uPA) and the conversion of plasminogen to
plasmin. Since plasmin is a potent activator of transforming
growth factor b1, a major pro-ﬁbrogenic protein, it might also
be predicted that PAI-1 deﬁcient mice would have elevated lev-
els of activated TGFb1, but this has not yet been evaluated.
Thus, mechanisms that inﬂuence ﬁbrogenesis in WT and
PAI-1 deﬁcient mice need additional study.
To clarify the role of PAI-1 in hepatic ﬁbrosis after biliary
tract obstruction at times with more established ﬁbrosis, we
have now determined the extent of activation of tPA, uPA,
plasmin and their substrates in mice 3 weeks after BDL. We
also determined the degree of collagen accumulation in WT
and PAI-1/ mice at this time point. In agreement with the
prior report [8], the current investigation demonstrates that he-blished by Elsevier B.V. All rights reserved.
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and that tPA activation is increased after BDL in PAI-1/
compared to WT mice. This tPA activation correlates with
the activation of known tPA substrates MMP9 and HGF, pro-
teins that should reduce hepatic ﬁbrosis. However, in contrast
to the study by Bergheim et al. we ﬁnd that uPA and plasmin
levels are equivalent in PAI-1/ and WT mice after BDL.
Supporting these data is the observation that uPA and plasmin
substrates MMP2 and TGF-b1 are also equivalent in WT and
PAI-1/ mice after BDL. Thus, for the ﬁrst time, we
demonstrate a distinct role of tPA, instead of uPA, in PAI-1
associated liver ﬁbrosis. These data suggest that PAI-1 is
pro-ﬁbrogenic primarily because it reduces tPA activation
after BDL.2. Materials and methods
2.1. Mouse model
Male 8–10 weeks old (22–26 g) WT (#0664) and PAI-1/ C57BL/6J
mice (#2507) from the Jackson Laboratory (Bar Harbor, ME) under-
went BDL. The common bile duct was double ligated below the bifur-
cation, single ligated above the pancreas and transected between the
ligatures under methoxyﬂurane (Schering-Plough Co., Union, NJ)
anesthesia. Sham mice underwent similar laparotomy without BDL.
Three to ﬁve mice of each genotype with sham surgery and 5–7 mice
of each genotype with BDL at each time point were sacriﬁced to obtain
blood and liver samples. The use and humane care of mice were ap-
proved by Washington University’s Animal Care Committee.
2.2. Fibrosis analysis
Morphometric analysis of Masson’s trichrome and Sirius red stained
liver sections [9] was performed on digital images (40·) of entire liver
sections using NIH imageJ 1.30 (NIH, Bethesda, MD). Fibrotic area
% = [collagen area/(total area  vascular lumen area)] · 100%.
Hydroxyproline content was measured colorimetrically [9,10] with
comparison to L-hydroxyproline standards.
2.3. HGF and smooth muscle a-actin (a-SMA) immunoblot
HGF immunoblot and a-SMA immunoblot analysis was performed
as described [2]. Primary antibodies: anti-human a-SMA (1:100, clone
1A4, Dako) [11], goat polyclonal anti-human a-HGF antibody (1:100,
N-17, Santa Cruz) [12,13].
2.4. a-SMA immunohistochemistry
Activated stellate cell marker a-SMA antibody (1:500, clone 1A4,
Dako) [9] was used with secondary biotinylated IgG and Tyramide
ampliﬁcation (NEN Life Science Products, Boston, MA). Morphomet-
ric analysis were performed as described above.
2.5. MMP-2, MMP-9, tPA, uPA and plasmin activity
Casein and plasminogen zymography for tPA, uPA and plasmin
activities was performed as described [2]. For MMP activity, gelatin
zymography was performed similarly except 10% Novex ZymogramTable 1
Primers used for qRT-PCR
Gene symbol UniGene name
GAPDH Glyceraldehyde-3-phosphate dehyd
Col1-a1 Procollagen I alpha 1
a-SMA Smooth muscle actin, alpha 2
a50to 3 0 sequences; f = forward primer; r = reverse-strand primer.gels containing 0.1% gelatin (Invitrogen, Carlsbad, CA) were used. He-
patic plasmin activity was also measured using a ﬂuorogenic substrate
as described [2].
2.6. TGF-b1 immunoassay (EIA)
Two hundred microgram liver homogenate protein was analyzed for
TGF-b1 using a Quantikine TGF-b1 EIA kit (R&D Systems Inc.,
Minneapolis, MN). Latent TGF-b1 was activated in 40 lL samples
with 1 N HCl (9 lL) and later neutralized with 1.2 N NaOH (6 lL).
2.7. Quantitative real time reverse transcriptase polymerase chain
reaction (qRT-PCR)
mRNA isolated using Micro-FastTrack 2.0 mRNA kit (Invitrogen,
Carlsbad, CA) was reverse transcribed (SMART PCR cDNA syn-
thesis kit, Clontech Inc., Palo Alto, CA). qRT-PCR was performed
in duplicate using SYBR green PCR Master mix (Applied Biosystems)
and an iCycler iQ (Bio-Rad). Primers are in Table 1 and Ref. [2]. RNA
content was normalized to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA.
2.8. Statistical analysis
Data were reported as mean ± S.E.M. Statistical analyses used Stu-
dent t test or Mann–Whitney rank sum test. P < 0.05 was considered
signiﬁcant.3. Results
3.1. PAI-1 mRNA level remains elevated after BDL
The ﬁnal common pathway for many types of liver injury in-
cludes stellate cell activation and collagen accumulation, even-
tually resulting in cirrhosis. Although PAI-1 mRNA was
previously reported to be elevated shortly after BDL [2,8],
whether PAI-1 elevation persists is not yet known. To deter-
mine if PAI-1 mRNA levels remain elevated 3 weeks after
BDL, qRT-PCR was performed and demonstrated a marked
elevation in PAI-1 mRNA compared to sham operated mice
(fold change: BDL 41.7 ± 11.0 versus sham surgery 1.1 ± 0.1,
P < 0.01). This suggests that persistent PAI-1 elevation may
contribute to long-term changes in the liver in the setting of
extrahepatic cholestasis.
3.2. PAI-1 deﬁciency reduces hepatic ﬁbrosis after BDL
An earlier report suggested that PAI-1 deﬁciency reduces he-
patic ﬁbrosis 2 weeks after BDL [8]. To conﬁrm and extend
this observation, morphometric analysis of collagen deposition
as demonstrated by Sirius Red and Masson’s trichrome was
performed on liver section obtained 3 weeks after BDL in
WT and PAI-1/ mice (Fig. 1A–C). This analysis demon-
strated 18–26% reductions in hepatic ﬁbrosis after BDL
(P 6 0.03) in PAI-1/ compared to WT mice, but compara-







Fig. 1. Hepatic collagen content is lower in PAI-1/ than in WT mice
after BDL. (A) Representative Sirius red stained liver sections were
obtained 3 weeks after BDL (40·, Scale bar = 300 lm). (B, C)
Quantitative image analysis of collagen ﬁbers with Masson’s trichrome
or Sirius red staining 3 weeks after BDL demonstrates that PAI-1/
mice develop less ﬁbrosis than WT animals. (D) Quantitative analysis
of hepatic hydroxyproline content in liver tissue 3 weeks after BDL
conﬁrms reduced collagen content in PAI-1/ compared to WT mice.
Data represent means ± S.E.M. for 3–5 sham and 5–7 BDL mice.
#P 6 0.03 versus WT. *P < 0.001 versus sham of the same genotype.
Fig. 2. Gel zymography analysis of tPA, uPA, and plasmin activity in
WT and PAI-1/ mice. (A) Casein/plasminogen zymography dem-
onstrated the level of active uPA, tPA and plasmin in the liver at 3
weeks after BDL. (B) Quantitative analysis of casein/plasminogen
zymography demonstrated increased tPA activity in the liver of PAI-
1/ versus WT animals after BDL, but no signiﬁcant diﬀerences in
uPA or plasmin activity after BDL and no diﬀerence in tPA, uPA or
plasmin activity after sham surgery. Data represent means ± S.E.M.
for 3–5 sham and 5–7 BDL mice. *P 6 0.02 versus WT.
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conﬁrmed by measuring hepatic hydroxyproline content
(Fig. 1D). Thus, consistent with a previous report [8], PAI-1
deﬁciency attenuates liver ﬁbrosis at later time points after
BDL.
3.3. PAI-1 deﬁciency increases tPA activity after BDL, but not
uPA or plasmin activity
PAI-1 inhibits tPA and uPA. Since tPA and uPA are plas-
minogen activators, it might also be expected that PAI-1
would inhibit plasminogen activation as it does in classically
described ﬁbrinolytic pathways [3]. Indeed, another group re-cently reported that both uPA and tPA activity were elevated
in PAI-1/ compared to WT mice after BDL [8]. In contrast,
we had previously found that tPA activity was elevated in PAI-
1/ compared to WT mice, but uPA and plasmin activity
were equivalent [2]. To determine if tPA and uPA are activated
in a more established liver ﬁbrosis model, we measured the
activity of these proteins and their mRNA levels in PAI-1/
and WT mouse liver 3 weeks after BDL using casein/plasmin-
ogen zymography and qRT-PCR, respectively. These studies
demonstrated equivalent tPA and uPA mRNA levels in WT
and PAI-1/ mice after BDL. Furthermore, although uPA
enzymatic activity was not statistically diﬀerent between WT
and PAI-1/ mice, tPA enzymatic activity was 43% higher
in PAI-1/ than WT mice 3 weeks after BDL (Fig. 2,
P = 0.02), but comparable in WT and PAI-1/ after sham
surgery. Together these data suggest that PAI-1 is an impor-
tant regulator of tPA activity after cholestatic liver injury,
but that uPA activity is primarily controlled by other mecha-
nisms.
Because tPA activates plasminogen by proteolysis to plas-
min, one might hypothesize that increased tPA activity in
PAI-1/ mice after BDL would cause higher plasmin activity.
To test this hypothesis we measured hepatic plasmin activity
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activity levels in WT and in PAI-1/ mice 3 weeks after
BDL. These ﬁndings were conﬁrmed using a ﬂuorogenic plas-
min substrate assay (data not shown). Plasminogen mRNA
levels were also equivalent in WT and PAI-1/ mice after
BDL. Together these data suggest that mechanisms other than
PAI-1 control hepatic plasmin activity after BDL.3.4. TGF-b1 activation, stellate cell activation and collagen
synthesis are equivalent in PAI-1/ and WT mice before
and after BDL
The extent of ﬁbrosis depends on rates of collagen synthesis
and degradation. Because PAI-1/ mice have reduced colla-
gen accumulation after BDL, we were interested in determin-
ing whether rates of collagen production were also reduced.
Stellate cell activation is an important mechanism of hepatic
ﬁbrogenesis and TGF-b1, a key stellate cell activator, is pro-
duced as an inactive precursor that can be activated by plas-
min. Active and latent TGF-b1 levels were therefore
measured in liver homogenates by enzyme immunoassay.
Although active and latent TGF-b1 were elevated at 1 and 3
weeks after BDL compared to sham surgery (Fig. 3A), PAI-
1 deﬁciency, did not inﬂuence the level of active or latent
TGF-b1 in liver homogenates. Pro-collagen I alpha 1 mRNA
levels were also comparable in WT and PAI-1/ mice after
BDL (Fig. 3B).
To evaluate stellate cell activation, we performed liver
immunohistochemistry for the activated stellate cell marker
a-SMA. While hepatic a-SMA+ cells increased dramati-
cally after BDL, there was no diﬀerence between WT and
PAI-1/ mice (Fig. 4A and B). These results were conﬁrmed
by measuring a-SMA mRNA using qRT-PCR (Fig. 4C) andFig. 3. TGF-b1 activation and pro-collagen I a1 mRNA production
are equivalent in WT and PAI-1/ mice after BDL. (A) Active and
latent hepatic TGF-b1 levels as measured by EIA are equal in WT and
PAI-1/ mice at 1 and 3 weeks after BDL. (B) Pro-collagen I a 1
mRNA levels as evaluated by qRT-PCR are equal at 1 week and 3
weeks after BDL in WT and PAI-1/ mice. Data represent
means ± S.E.M. for 3–5 sham and 5–7 BDL mice. #P < 0.01 versus
sham mice of the same genotype.
ig. 4. Stellate cell activation is equivalent in WT and PAI-1/ mice
fter BDL. (A) Stellate cell activation 3 weeks after BDL was
valuated by a-SMA immunohistochemistry (100·, scale bar =
50 lm) and cell morphology. Arrows show a-SMA expression in
lood vessels. Inserts with arrow head show the morphology of
ctivated stellate cells (scale bar = 50 lm). (B) Quantitative image
nalysis of a-SMA positive area 3 weeks after BDL demonstrates that
AI-1/ and WT mice have equivalent amount of stellate cell
ctivation. (C) Quantitative real-time PCR demonstrates that mRNA
xpression of a-SMA in liver 3 weeks after BDL is equivalent in PAI-
/ and WT mice. (D) Hepatic a-SMA levels determined by protein
munoblot analysis are equivalent in WT and PAI-1/ mice at 1
eek and 3 weeks after BDL. Data represent means ± S.E.M. for 3–5















gby protein immunoblot analysis (Fig. 4D). Collectively these
data demonstrate that PAI-1 deﬁciency does not inﬂuence he-
patic collagen accumulation by aﬀecting collagen production
or stellate cell activation.
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BDL
Because PAI-1 deﬁciency does not alter collagen production
after BDL, we hypothesized that reduced ﬁbrosis in PAI-1/
mice was due to increased collagen degradation. Since tPA in-
creases MMP-9 synthesis [14] while uPA increases both MMP-
2 and MMP-9 activity [15,16], we measured MMP-2 and
MMP-9 activity in liver homogenates 3 weeks after BDL using
gelatin zymography. Both pro-MMP-9 and MMP-9 were sig-
niﬁcantly elevated in PAI-1/ compared to WT liver
(Fig. 5). In contrast, pro-MMP2 and MMP2 levels were com-
parable in WT and PAI-1/ mice. Collectively, these data sug-
gest that reduced collagen accumulation in PAI-1/ mice after
BDL results from increased collagen degradation rather than
reduced collagen synthesis.Fig. 5. Gel zymography analysis of MMP-9 and MMP-2 activity in
WT and PAI-1/mice. (A, B) Gelatin zymography demonstrated both
active and pro-MMP proteins (MMP-2 and MMP-9) in the liver after
BDL. (A) Zymogram was incubated 18 h to demonstrate MMP-9
activity. (B) Zymogram was incubated for 42 h to demonstrate MMP-2
activity. (C) Quantitative analysis of gelatin zymography demonstrates
increased MMP-9, but not increased MMP-2 levels in PAI-1/ mice
compared to WT animals 3 weeks after BDL. Data represent
means ± S.E.M. for 5–7 BDL mice. *P < 0.01 versus WT.
Fig. 6. Protein immunoblot analysis demonstrates increased mature
and a-HGF in PAI-1/ mouse liver after BDL compared to WT mice.
(A) Liver homogenates were analyzed by immunoblot with an
antibody to a-HGF. Bands representing pro-HGF, non-reduced a,b-
chain mature HGF, and a-chain HGF (reduced mature HGF) are
indicated. (B) Quantitative analysis of HGF at 3 weeks after BDL
demonstrated increased mature a-HGF in PAI-1/ mice. HGF levels
were equivalent in WT and PAI-1/ mice after sham surgery. Data
represent means ± S.E.M. for 3–5 sham and 5–7 BDL mice. *P 6 0.02
versus WT at the same time point.3.6. PAI-1 deﬁciency increases hepatocyte growth factor (HGF)
activation
Our recent analysis of early events after BDL in PAI-1/
mice demonstrated increased HGF activation in mutant ani-
mals [2]. To determine if increased HGF activation persisted
3 weeks after BDL in PAI-1/ mice, we performed protein
immunoblot analysis (Fig. 6). These studies conﬁrmed elevated
active HGF in PAI-1/ compared to WT mice after BDL, but
normal levels of active HGF after sham surgery. This increase
in active HGF may in part explain the increased pro-MMP9
levels [17,18] observed in PAI-1/ mice.4. Discussion
Liver ﬁbrosis represents a wound-healing process character-
ized by stellate cell activation and collagen deposition in re-
sponse to a variety of chronic injury stimuli [19,20]. Collagen
deposition reﬂects the balance between production and degra-
dation. PAI-1 could potentially inﬂuence both collagen pro-
duction and collagen degradation by controlling proteolytic
processing of key regulatory molecules and the ECM. For sev-
eral reasons we hypothesized that PAI-1 deﬁciency would in-
crease collagen production. First, PAI-1 deﬁciency was
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turn, should have increased conversion of plasminogen to plas-
min [3]. Because plasmin is a prominent TGF-b1 activator and
TGF-b1 stimulates stellate cell activation and collagen produc-
tion [21,22], we predicted increased plasmin activity, increased
TGF-b1 activation, increased stellate cell activation, and in-
creased collagen production in PAI-1/ compared to WT
mice after BDL. All of these predictions were proved wrong
in this study. In contrast, we also predicted increased tPA pro-
teolytic activity would activate HGF and matrix metallopro-
teinases that could reduce hepatic ﬁbrosis after BDL. These
predictions were demonstrated correct in this report.
In agreement with an earlier study indicating that collagen I
alpha 1 mRNA levels were equivalent in PAI-1/ and WT
shortly after BDL [8], we also found comparable levels of col-
lagen I alpha 1 mRNA in PAI-1/ and WT mice 3 weeks after
BDL. Therefore, the simplest explanation for reduced collagen
accumulation in PAI-1/ mice, is that collagen degradation is
increased by PAI-1 deﬁciency. While ECM remodeling is a
complex process involving a variety of proteases and protease
inhibitors [23], we focused on MMP2 and MMP9 because they
have altered expression after hepatic injury and have been
hypothesized to inﬂuence ﬁbrosis [24–27]. Furthermore, their
activity is inﬂuenced by plasminogen activators. Our studies
directly demonstrate increased pro-MMP9 and MMP9 in
PAI-1/ compared to WT mice after BDL. In contrast, pro-
MMP2 and MMP2 activity were equivalent in PAI-1/ and
WT mice. These observations are consistent with known eﬀects
of tPA on MMP9 activation [14]. In contrast uPA inﬂuences
both MMP2 and MMP9 [15,28]. Thus, the lack of MMP2 ele-
vation in our studies is consistent with the similar uPA activity
in PAI-1/ and WT mice. One additional explanation for the
increase in pro-MMP9 in PAI-1/ mice is the previously de-
scribed ability of HGF to increase MMP9 synthesis [17] and
increased HGF activation in PAI-1/ mice.
Our new data demonstrating that uPA and plasmin activities
are equivalent in WT and PAI-1/ 3 weeks after BDL, but
tPA activity is elevated are also consistent with our previous
observation that uPA and plasmin activities were similar at
72 h [2,8] and 1 week [2] after BDL. In contrast, another group
recently reported elevated uPA activity levels in PAI-1/ com-
pared to WT mice 2 weeks after BDL [8]. While the explana-
tion for these discrepant ﬁndings is not clear, similar eﬀects
of PAI-1 deﬁciency on tPA, but not uPA were also observed
in a renal injury model [7,29] and an arthritis model [30] sug-
gesting that factors other than PAI-1 critically regulate plas-
min and uPA at least in some settings. For example, plasmin
is also regulated by Serpinf 2 [31]. Given the equivalent levels
of plasmin activity in PAI-1/ compared to WT mice after
BDL, the ﬁnding that TGF-b1 activity, stellate cell activation
and collagen production were equivalent in PAI-1/ and WT
mice is more easily understood because plasmin is one of the
more important TGF-b1 activators.
Interestingly, the reduction in ﬁbrosis in PAI-1/ mice after
BDL in this report appears less dramatic than the reduction in
ﬁbrosis in other model systems [6–8]. Furthermore, blocking
PAI-1 is not always protective. For example, PAI-1/ mice
have dramatically more severe renal injury than WT animals
in a passive anti-glomerular basement membrane glomerulone-
phritis model [32]. In this case, PAI-1 deﬁciency increases
both uPA and tPA activity. Furthermore, both tPA and uPA
can activate latent TGF-b in vitro [32]. Thus, the eﬀect ofPAI-1 deﬁciency on both injury and repair may critically de-
pend on the type of injury and organ aﬀected. This is not sur-
prising since distinct regulatory systems may be more
important in some tissues than others and mechanisms con-
trolling ﬁbrosis are complex. For example, latent TGF-b1 is
activated not only by tPA, uPA and plasmin, but also by
MMP2, MMP9, thrombospondin-1, and by some integrins
(avb6 and avb8) [33]. Thus, the eﬀect of altering PAI-1 depends
on cellular context and the expression of other key regulatory
molecules.
Together these studies suggest PAI-1 inhibition may be use-
ful as part of a strategy to prevent cirrhosis resulting from bil-
iary tract obstruction. Because our study has shown that
blocking PAI-1 increases HGF activation and reduces ﬁbrosis
by increasing ECM degradation, this approach might be par-
ticularly useful in combination with strategies to reduce stellate
cell activation and collagen synthesis. Furthermore, while sev-
eral recent approaches to preventing ﬁbrosis have focused on
increasing uPA [16,28,34], these new data suggest that in-
creased tPA activity may also prevent ﬁbrosis and that tPA
and uPA have distinct roles in controlling liver injury after bil-
iary tract obstruction. Consistent with this result, we also have
data to demonstrate a critical role for tPA in reducing hepatic
injury after BDL [35]. These analyses not only demonstrated
that tPA deﬁciency increases hepatic injury, but also demon-
strated that essentially all of the early protective eﬀects of
PAI-1 deﬁciency after BDL in mice could be prevented by
blocking tPA.
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